98%
921
2 minutes
20
Objectives: The risk of stroke is increased in patients with bipolar disorder. Lithium exhibits neuroprotective effects but the association between lithium use and the risk of stroke is unknown.
Methods: A population-based retrospective cohort study was conducted by utilizing the National Health Insurance Research Database in Taiwan. Subjects who had first been diagnosed with bipolar disorder between 2001 and 2006 were identified. A propensity score (PS) for receiving lithium was calculated with variables of age, gender, and comorbidities. The patients with bipolar disorder receiving lithium within the period from diagnosis through to December 2011 were designated as the lithium group (n = 635). A 1:2 ratio was used to select PS-matched subjects with bipolar disorder without lithium use (n = 1,250). Multivariate Cox proportional hazards regression models were used to explore the association, rather than causal inference, of lithium exposure and the risk of stroke.
Results: Of the 1,885 subjects, 86 (4.6%) experienced stroke, including 2.8% of the lithium group and 5.4% of the non-lithium group. Lithium use was associated with a significantly reduced risk of stroke [hazard ratio (HR) = 0.39, 95% confidence interval (CI): 0.22-0.68]. Reduced risks of stroke were also associated with the highest cumulative lithium dose [≥720 defined daily dose (DDD), HR = 0.25, 95% CI: 0.10-0.59], the longest cumulative exposure period (≥720 days, HR = 0.20, 95% CI: 0.06-0.64), and the highest exposure rate (≥2 DDD/day, HR = 0.39, 95% CI: 0.21-0.70).
Conclusions: Lithium use was significantly related to a reduced risk of stroke in patients with bipolar disorder.
Download full-text PDF |
Source |
---|---|
http://dx.doi.org/10.1111/bdi.12336 | DOI Listing |
Front Nutr
August 2025
Faculty of Medicine, Department of Psychiatry, Medical University of Gdańsk, Gdańsk, Poland.
Unlabelled: Mood disorders, including major depressive disorder (MDD) and bipolar disorder (BP), significantly impact global health, with MDD affecting over 300 million people and BP affecting approximately 2% of the world's population. Ketamine, originally an anesthetic, has emerged as a promising treatment for patients with treatment-resistant depression (TRD), due to its unique pharmacological properties, such as N-methyl-D-aspartate (NMDA) receptor antagonism and anti-inflammatory effects. The potential of ketamine in treating depression has sparked debate regarding its effects on appetite.
View Article and Find Full Text PDFAlpha Psychiatry
August 2025
Department of Psychiatry, Bakirkoy Research and Training Hospital for Psychiatry, Neurology and Neurosurgery, 34147 Istanbul, Turkey.
Objective: In bipolar disorder, residual mood symptoms often persist even during the euthymic period, impairing functionality in 30-60% of patients in clinical remission. Addressing residual symptoms is critical as they are linked to reduced functionality and subjective wellbeing. This cross-sectional study aimed to determine the relationship between mindful attention awareness (MASS) and residual symptom severity in bipolar I disorder.
View Article and Find Full Text PDFJ Appl Toxicol
September 2025
Department of Drug and Cosmetics Technology, Faculty of Pharmaceutical Sciences in Sosnowiec, Medical University of Silesia in Katowice, Sosnowiec, Poland.
Phenothiazine derivatives have been used for decades as antipsychotic drugs in multiple mental health and physical conditions treatment (schizophrenia, mania in bipolar disorder, and psychosis). Epidemiological studies have shown that people with schizophrenia are less likely to suffer from cancer, which indicates the ability of antipsychotics to inhibit the development of cancer cells. It is our third review about the impact of phenothiazine derivatives on cell death.
View Article and Find Full Text PDFComput Med Imaging Graph
August 2025
Beijing Huilongguan Hospital, Peking University Huilongguan Clinical Medical School, Beijing 100096, China. Electronic address:
Bipolar disorder (BD) is a debilitating mental illness characterized by significant mood swings, posing a substantial challenge for accurate diagnosis due to its clinical complexity. This paper presents CS2former, a novel approach leveraging a dual channel-spatial feature extraction module within a Transformer model to diagnose BD from resting-state functional MRI (Rs-fMRI) and T1-weighted MRI (T1w-MRI) data. CS2former employs a Channel-2D Spatial Feature Aggregation Module to decouple channel and spatial information from Rs-fMRI, while a Channel-3D Spatial Attention Module with Synchronized Attention Module (SAM) concurrently computes attention for T1w-MRI feature maps.
View Article and Find Full Text PDFTransl Psychiatry
September 2025
Department of Human Sciences, The Ohio State University, Columbus, OH, USA.
A ketogenic diet (KD) has shown promise as an adjunctive therapy for neurological and neuropsychiatric disorders, including bipolar disorder and major depressive disorder (MDD). We examined tolerance for a KD in young adults with MDD and assessed symptoms of depression and metabolic health. Students (n = 24) with a confirmed diagnosis of MDD at baseline receiving standard of care counseling and/or medication treatment were enrolled in a 10-12 week KD intervention that included partial provision of ketogenic-appropriate food items, frequent dietary counseling, and daily morning tracking of capillary R-beta-hydroxybutyrate (R-BHB).
View Article and Find Full Text PDF